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Historically, pharmaceutical aerosols have been employed for the treatment of obstructive
airway diseases, such as asthma and chronic obstructive pulmonary disease, but in the
past decades their use has been expanded to treat lung infections associated with cystic
fibrosis and other respiratory diseases. Tuberculosis (TB) is acquired after inhalation of
aerosol droplets containing the bacilli from the cough of infected individuals. Even though
TB affects other organs, the lungs are the primary site of infection, which makes the
pulmonary route an ideal alternative route to administer vaccines or drug treatments.
Optimization of formulations and delivery systems for anti-TB vaccines and drugs, as well
as the proper selection of the animal model to evaluate those is of paramount importance
if novel vaccines or drug treatments are to be successful. Pharmaceutical aerosols for
patient use are generated from metered dose inhalers, nebulizers, and dry powder inhalers
(DPIs). In addition to the advantages of providing more efficient delivery of the drug, low
cost, and portability, pharmaceutical dry powder aerosols are more stable than inhalable
liquid dosage forms and do not require refrigeration. Methods to manufacture dry powders
in respirable sizes include micronization, spray drying, and other proprietary technologies.
Inhalable dry powders are characterized in terms of their drug content, particle size,
and dispersibility to ensure deposition in the appropriate lung region and effective
aerosolization from the device. These methods will be illustrated as they were applied
for the manufacture and characterization of powders containing anti-tubercular agents and
vaccines for pulmonary administration. The influence of formulation, selection of animal
model, method of aerosol generation, and administration on the efficacy demonstrated
in a given study will be illustrated by the evaluation of pharmaceutical aerosols of anti-TB
drugs and vaccines in guinea pigs by our group.
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INTRODUCTION
Despite being treatable and, indeed, preventable, tuberculosis
(TB) continues to be a major public health challenge in many
parts of the world (Fair et al., 2007). The number of people
infected with TB is growing as reflected by world-wide increases
in new cases at an incidence rate of 1.8% per year between 1997
and 2000 (Corbett et al., 2003). In 1993, the number of people
infected with TB in the world was so large that the World Health
Organization (WHO) declared it “a global emergency” (Expert
Committee, 2006). Recently, a survey by the WHO estimated that
one third of the world population (≈2 billion) is infected with
tubercle bacilli, 8 million people develop active disease and 2 mil-
lion die of TB each year (Barnes and Cave, 2003; Frieden et al.,
2003).
In 1995, the WHO recommended the implementation of
a treatment strategy called Directly Observed Therapy, Short-
course (DOTS). The aim was to treat TB infected patients by
directly observing them to take their medication (isoniazid,
rifampicin, pyrazinamide, and streptomycin or ethambutol or
both) for at least the first two months of treatment. This ensured
that the medication was taken in the right combinations and
appropriate dosage, which has reduced the incidence of multi-
drug resistant TB. It is anticipated that 80% of deaths attributed to
TB world-wide will be prevented by using DOTS. The estimated
global incidence rate of TB peaked around 2003, but after the
successful introduction of DOTS it decreased between 2005 and
2006 (WHO, 2008). In 2006, the incidence rate stabilized in the
European Region and continued to decline slowly in the other five
WHO regions of the world. The WHO estimates that the preva-
lence and death rates have been falling longer and faster than the
incidence rate.
A person is infected with TB shortly after the inhala-
tion of coughed/sneezed droplets containing as few as 3–5
Mycobacterium tuberculosis bacilli from an already infected per-
son (Dannenberg, 1999). The first host defense is the alveolar
macrophages that scavenge the alveolar surface ingesting the
bacilli and becoming non-specifically activated during the pro-
cess. If the host is immunocompetent, the bactericidal capac-
ity of the macrophage will destroy the bacteria or limit its
multiplication, but if the host is immune-compromised or
has a weak immune response, M. tuberculosis bacilli (MTB)
is able to counteract the host’s defenses. MTB can impair
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innate macrophage anti-microbial mechanisms by inhibiting the
phagosome-lysosome fusion (Nardell, 1993). If the macrophage
is able to defeat the host defense, MTB can replicate within the
macrophage causing it to rupture. Thus, the main weapons of
MTB against the human host are its ability to multiply logarith-
mically within non-activated macrophages and extracellularly in
liquefied caseous material, including those proximal to the lumen
of cavities. For these reasons, this bacterium is considered to
be among the most successful and poorly understood pathogens
affecting human beings.
After the rupture of infected macrophages, immature
macrophages (monocytes) are attracted from systemic circula-
tion by chemotactic factors initiating the granuloma formation
(Nardell, 1993). Macrophages are also responsible to process the
antigens of MTB and present them to the specific T lymphocytes,
although recent theories suggest that dendritic cells and alveolar
macrophages may share this role (Kaufmann, 2004). Likewise the
current dogma is that cell mediated immunity (CMI) is the only
defense of the host toMTB, but others had suggested thatmucosal
immunity may also be important (Dietrich et al., 2006). Even
before the CMI is mounted completely in the host, MTB is able to
escape the lung environment and enter the bloodstream to spread
to other organs, notably the spleen and liver. All of these events
can occur even before is noted that a patient has been infected.
The tuberculin skin test has been used as a method to diag-
nose TB in epidemiological studies in humans and cattle for more
than half a century (De Souza, 2009). It consists of an intradermal
injection of a purified protein derivative (PPD), a poorly defined
mixture of M. tuberculosis antigens containing both secreted and
somatic proteins. Some of the mycobacterial antigens contained
in PPD are shared among pathogenic mycobacteria belonging
to the M. tuberculosis complex (M. tuberculosis, M. bovis, and
M. africanum), environmental non-tuberculous mycobacteria
(NTM), and the vaccine substrain M. bovis bacille Calmette-
Guerin (BCG) (Van Pinxteren et al., 2000). Thus, although
responses to PPD are an important aid in the diagnosis of TB
and can give an indication of exposure to mycobacteria, it is often
impossible to distinguish BCG vaccination and exposure to NTM
from M. tuberculosis infection. Therefore, it has been apparent
that a new diagnostic reagent with specificity for M. tuberculosis
andM. bovis is needed to overcome the limitations of PPD (Hanif
et al., 2010b).
BCG vaccination is considered the most important tool to
protect against TB. According to the WHO, more people alive
today have been vaccinated with the live attenuated BCG vaccine
than with any other vaccine. In spite of its widespread use and
many advantages like being inexpensive, safe at birth, given as
a single shot, and provision of some protection against leprosy,
BCG vaccination remains controversial. Its protective efficacy
has varied widely in different parts of the world and its impact
on the global problem of TB remains unclear (Rodrigues and
Smith, 1990; Haile and Kallenius, 2005). Estimates of protec-
tion imparted by BCG against pulmonary TB vary greatly from
0 to 80% (Castanon-Arreola and Lopez-Vidal, 2004). A trial
in British school children, in 1952, showed 77–84% efficacy
(Rodrigues and Smith, 1990), where as the Chingleput trial in
India showed zero efficacy of protection provided by the BCG
vaccine (Tripathy, 1987). This variability has been attributed to
various factors including strain variation in BCG preparations,
environmental influences such as sunlight exposure, poor cold-
chain maintenance, genetic or nutritional differences between
populations and exposure to environmental mycobacterial infec-
tions (Bloom and Fine, 1994; Fine, 1995; Haile and Kallenius,
2005).
Implementation of BCG vaccination faces two other prob-
lems; BCG vaccination induces a delayed type hypersensitivity
(DTH) response that cannot be distinguished from exposure to
M. tuberculosis as BCG and PPD are sharing most of the antigens,
making the use of tuberculin skin test unreliable for diagnostic
or epidemiological purposes (Lowrie et al., 1995; Mustafa and
Al-Attiyah, 2003; Teixeira et al., 2006). Second, it cannot be used
indistinctly in all populations, as the WHO has recommended
that children with symptoms of HIV infection should receive all
the vaccines except BCG (Hesseling et al., 2003; Pardini et al.,
2006). The reason is that BCG is a live attenuated vaccine that
may cause disease in immune-compromised people rather than
giving immunity. Thus, there is an urgent need to develop more
specific and safer vaccines against MTB. Development of a vac-
cine that would provide better protection than BCG (either whole
organism or subunit vaccines) requires the identification of the
immunological mechanisms that lead to protection against infec-
tion and of the antigens recognized by those protective responses
(Hanif et al., 2010a).
Treatment of TB infection is an arduous and lengthy process
requiring daily co-administration of 2–4 antibiotics for at least six
months (Fox et al., 1999). For most patients, regimens that con-
tain the first line drugs rifampicin and isoniazid can be completed
in six months if pyrazinamide is included and in nine months, if
pyrazinamide is omitted. However, treatment for bacterial strains
resistant to isoniazid or rifampicin that require the use of sec-
ond line drugs such as capreomycin, amikacin or kanamycin are
continued for minimum of 12 months for up to 24 months. The
extended use of these antibiotics frequently produces unwanted
side effects in patients due to intrinsic drug toxicity. During this
extended therapy, patients may terminate treatment early due
to many factors like unwanted side effects or alleviation of pri-
mary symptoms (Thomas, 2002). Partial treatment can make the
disease more difficult to treat since selection of drug resistant
mutants of M. tuberculosis may occur (Garcia-Contreras et al.,
2010).
The world-wide increase in the incidence of TB, inadequate,
and non-specific immunological methods of diagnosis, the failure
of BCG vaccine to protect against TB in all populations and the
lengthy treatment duration have spurred the need for improved
diagnostic tests, new vaccines, and new therapies against a disease.
Thus, successful strategy to control TB on a global scale requires:
(1) improved methods for early diagnosis of an infection; (2) an
effective vaccine that can be given safely to all populations and
in all parts of the world to protect against all forms of the dis-
ease; and (3) advances in TB therapy that reduces frequency of
dosing and over all treatment time and side effects, that can be
effective against MDR/XDR and safe for HIV infected TB patients
(Mustafa, 2009; Garcia-Contreras et al., 2010). Recent advances in
these areas will be covered in the following sections.
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ANIMAL MODELS
Animal models are extremely important in any type of research
as they allow manipulation of different variables involved that
may not be easy or feasible to do in human subjects. Initial
studies in virtually every area of pharmaceutical and pharmaco-
logical research have been performed in small rodents because
terminal procedures can easily be conducted and large number
of these animals can be used for statistical validity (Cryan et al.,
2007). Rats and guinea pigs are frequently used for the study of
drug delivery to lungs because a variety of dosing techniques that
requires a small amount of drug can be employed. However, to
study novel vaccines (not inhaled) and treatments for TB, a large
number of studies have used mice and fewer have used other
animal models including guinea pigs, rabbits, monkeys, and non-
human primates. Among the advantages that make the mouse the
animal model most used in TB studies are the vast knowledge of
its immune system, the large variety of reagents available to study
their immune response, their cost, and the number of knock out
species available (Orme, 2003). In addition to the differences of
these species and humans in the progression of the disease, the
tidal volume and breathing frequency ofmice are significantly dif-
ferent from humans (Hickey and Garcia-Contreras, 2001; Cryan
et al., 2007), which makes delivery of large doses of aerosol to
mice is difficult to achieve in short periods of time and amount
of biological fluids that can be collected is small. This, plus the
fact that all rodents are obligate nose breathers makes this animal
model less than appropriate to study novel inhaled vaccines or
treatments for TB. Although rats can be comparable to humans
for the study of diseases such as influenza (Huang et al., 2003)
and pulmonary fibrosis (Spond et al., 2003), they are not very
susceptible to TB infection, neither by the IV route nor by aerosol
exposure (Ornstein and Steinbach, 1925).
The comparative biology of the guinea pig indicates that the
physiology of their pulmonary tract is quite similar to that of
humans; particularly the response of the lung to inflammatory
stimuli as well as the dermal response to both acute and chronic
inflammatory mediators (Wagner and Manning, 1976; Lechner
and Banchero, 1982). Hormonally and immunologically guinea
pigs are more like human than other rodents, thus they are
often used to model human infectious disease (McMurray, 1994).
Guinea pigs are susceptible to aerosol infection with only a few
MTB and the progression of the disease (bacillemic phase and for-
mation of granulomas) is similar to that in humans (McMurray,
2003). Guinea pigs are also considered the “gold standard” to
test the potency and standardize PPD for human use, since they
are the smallest species that can develop indurate delayed hyper-
sensitivity reaction in the skin after injection of this reagent
and the procedure can be performed without sacrificing the ani-
mal (McMurray, 2001). Besides the limitation in the number of
immunological reagents available to study responses in this ani-
mal model, they share with the other rodents the differences in
pulmonary function and respiratory parameters with humans.
This makes the administration of daily aerosol doses of anti-
tubercular drugs very difficult to match with the true inhaled
dose that can be achieved in a human. Thus, the selection of the
appropriate dosing device and the selection of a formulation opti-
mized for pulmonary delivery are critical for the success of this
approach. These factors will be discussed in subsequent sections.
Nevertheless, guinea pigs are an excellent model to test inhaled
vaccines that require on 1–3 administrations.
Merely from the delivery point of view, the easiness of aerosol
delivery to conscious animals and the amount of aerosol delivered
increase as the size of the animal increases. Rabbits, non-human
primates, and calves are larger animal models that have been
employed to study different aspects of TB infection and treat-
ment. Each of them has its particular advantages: rabbits is the
smallest animal model to study cavitary TB (Dharmadhikari
and Nardell, 2008), non-human primates are great models to
study co-infection of TB with HIV that can be applicable
to humans (Mattila et al., 2011), and calves are frequently used
to develop diagnostic reagents to differentiate between vaccinated
and infected individuals because large volumes of blood can be
drawn without sacrificing the animal (Pollock and Andersen,
1997). However, there are no studies reported in the literature that
use aerosol delivery of vaccines or drugs in these larger animal
models for the treatment or prevention of TB. Perhaps a reason
for this is the high cost associated with the purchase and mainte-
nance of these animals as well as ethical issues. It is conceivable
that after the efficacy of an approach is tested in the smaller ani-
mal models, a logical step would be to evaluate such approach in
a larger animal model, in which larger amounts of a therapeutic
aerosol may be delivered.
METHODS OF AEROSOL DELIVERY FOR
ANTI-TUBERCULAR DRUGS AND VACCINES
Even though metered dose inhalers are the devices most com-
monly used in inhaled therapies for humans, they are limited by
the size of the dose they can deliver with one puff. These small
dose sizes are suitable for potent therapeutics such as those used
in the treatment of asthma, but they are significantly smaller than
the doses required to deliver antibiotics for the treatment of a dis-
ease such as TB. Thus, it is not surprising that there are no reports
of their use in TB treatment or vaccines.
Perhaps the first documented use of inhaled therapy for TB
treatment in humans is the work of Paraf et al. in 1953 using liq-
uid aerosols of antibiotics (Paraf et al., 1953), whereas the first
use of an inhaled vaccine against TB was reported by Rosenthal
et al. (1968). Historically, most antibiotics and experimental vac-
cines that have been delivered by the pulmonary route have been
delivered from liquid formulations, and the aerosols have been
generated by nebulizers. Except for the Pari eflow, the Activaero
AKITA and the APIXNEB systems, most nebulizers are ineffi-
cient, delivering only about 10% of the initial vaccine/drug load
to the patient (Garcia-Contreras, 2012). This efficiency is signif-
icantly decreased when nebulization is used to deliver aerosol
to conscious rodents, because their much smaller lung capac-
ity and breathing frequency, and the fact that they only breathe
through their nose as explained in the previous section. Moreover,
the use of nebulizers to deliver vaccines has been reported to
decrease the potency of vaccines because of the shear force pro-
duced by the nebulizer to generate the aerosol (Coates et al.,
2006).
For animal studies, the limitations on the delivery of solutions
have been addressed by the use of direct administration methods.
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The main advantages of direct administration are that small and
relatively large doses of drug can be delivered by these meth-
ods and that the dose delivered can be accurately measured. The
main disadvantage is that the use of these methods for multiple
or consecutive dosing may not be recommended, since they are
performed under anesthesia or light sedation and the insertion
of the device may cause local irritation. Direct administration
methods for liquids include liquid instillation and spray instilla-
tion but only the latter delivers drug or vaccine in a form proxy
to true aerosol. In general, they involve visualization of the tra-
chea of the animal with the help of a laryngoscope to place a thin
stainless steel tube in the trachea, near the carina, to administer
drugs (Cryan et al., 2007). Liquid instillation, usually performed
with oral gavage needles, delivers drugs in the form of very large
and coarse droplets. Themain disadvantage of this method is that
the liquid may be distributed mainly in the larger airways and
an unknown amount of the drug may be coughed up or swal-
lowed (Hickey and Garcia-Contreras, 2001). Depending on the
volume delivered, it also may cause significant stress in the sub-
ject or have the risk of endangering the animal. These limitations
can be addressed by delivering solutions in smaller droplets pro-
duced by a sprayer which is denominated “spray instillation.” The
MicroSprayer™ (Penn Century, Philadelphia, PA) is an example
of such devices in which the aerosol is generated. The aerosol
is generated by the atomizer in the tip of a long, thin, stain-
less steel tube of the MicroSprayer™ to deliver the liquid vaccine
or drug. The size of the aerosol generated is influenced by the
physo-chemical characteristics (density, viscosity, concentration)
of the solutions/suspension to be delivered (García-Contreras and
Hickey, 2003).
Delivery of vaccines by direct administration methods is very
efficient and ensures that the entire dose is delivered to the
lung. For drugs, the use of direct administration methods is
of paramount importance to determine the pharmacokinetic
parameters of disposition after pulmonary delivery. The dose can
be accurately measured and delivered by direct administration,
but as explained earlier, when passive inhalation only a fraction of
the nominal (loading) dose will be actually deposited in the lungs.
Figure 1 illustrates this concept by comparing the plasma concen-
trations obtained after administration of the same nominal dose
of rifampicin by intratracheal instillation and by nebulization
(García-Contreras and Hickey, 2002).
Despite of all their advantages, direct administration meth-
ods may not be feasible for TB treatment since daily doses
of the antibiotics are required for an extended period of time
(weeks, in most cases). In addition to the risk of anesthetiz-
ing/sedating the animal multiple times, the repeated insertion
of the tube may cause tracheal irritation and exacerbate the
disease. Therefore, for studies of this nature, passive inhalation
methods are preferred. In general, the conscious animals are
placed in exposure chambers that can be for whole-body, head-
only, and nose-only (Dorato, 1990). Animals can be placed in
whole body chambers without restrain, but it is possible that
the aerosolized drug also may be absorbed by the oral and
percutaneous routes. In the first novel approach of its kind, a
custom made whole body exposure chamber was employed to
treat TB-infected guinea pigs with aerosols generated by an Acorn
FIGURE 1 | Plasma concentration versus time curves in guinea pigs
after administration of rifampicin suspension (RIF) by intratracheal
liquid instillation (ITA) and nebulization (NEB). (Average ± standard
deviation, n = 3–5). Modified from García-Contreras and Hickey (2002).
nebulizer from rifampicin suspensions (Suarez et al., 2001a,b).
A one-log reduction in the bacterial burden of the lungs of
these animals was reported after this treatment with rifampicin
aerosols. Commercial whole body exposure chambers include
those manufactured by CH technologies Inc. (Westwood, NJ) and
EMMS (Hants, UK).
Head-only and nose-only chambers are used when aerosol
exposure to other body parts needs to be restricted. These cham-
bers consist of a cubic or cylindrical reservoir with cylindrical
animal holders in its perimeter. The animal holders have a con-
ical shape with the narrowest part designed to fit the animal’s
nose. The aerosol is circulated in the main reservoir or in a central
duct and is distributed to all the animal holders. Commercially
available nose only chambers have the capacity to hold 4–48
animals at one time for aerosol exposure, including those man-
ufactured by CH Technologies (Westwood, NJ), Intox Products
(Edgewood, NM), TSE GmbH (Badhamburg, Germany), and
ADG Developments (Herts, UK). Providing that the mass flow
(dose rate) and particle size and distribution remain constant
during the aerosolization process, each animal will be exposed
to the same aerosol dose. The dose can be calculated as rec-
ommended by the Association of Inhalation Toxicologists (AIT)
from the aerosol concentration, the respiratory minute volume
of the animal and its weight, the duration of exposure, and
the respirable fraction of the aerosol (Alexander et al., 2008).
The exposure chamber manufactured by ADG Developments
is designed to deliver aerosols to approximately twenty rodents
(Garcia-Contreras, 2011) and was employed to deliver aerosols
generated by the Acorn nebulizer from rifampicin suspensions to
TB infected animals daily for four weeks (Garcia-Contreras et al.,
2006c). As a result of this treatment, a decrease was observed in
the bacterial burden of the spleens of these animals compared to
untreated controls.
An additional limitation of using solutions to deliver thera-
peutics (vaccines or drugs) against TB is the formulation of the
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therapeutic compound by itself. The properties and characteris-
tics of the formulation as solution or suspension are limited by the
solubility, stability, and sterility of drugs or vaccines in solution,
as well as their requirements for storage. This is further compli-
cated if the compound is completely insoluble or is formulated
into engineered particles, because it may be difficult to find a
biologically friendly media to suspend particles before nebuliza-
tion and the concentration that can be achieved in the suspension
may not be therapeutic for a given drug. Nebulization of highly
concentrated suspensions may also result in particle precipita-
tion in the nebulizer and the delivery of dilute aerosols (Smyth
et al., 2003). All these limitations observed with solutions and
suspensions have prompted researchers to find alternative formu-
lations and strategies to deliver inhaled therapeutics. Dry powder
formulations are considered the most stable from all inhaled
dosage forms and can be delivered by dry powder inhalers (DPIs).
Their popularity is such that several drugs previously formu-
lated into metered dose inhalers are nowmanufactured into DPIs.
Advantages of DPIs over nebulizers and metered dose inhalers
include: portability, low cost, and better control of the dose deliv-
ered. DPIs can be classified into single-dose ormulti-dose devices,
depending on the number of doses that can dispense, or into pas-
sive or active, depending on the mechanism of powder dispersion
(Hickey and Crowder, 2007). The efficiency of delivery for passive
DPIs is influenced by its mechanism of dispersion and the inspi-
ratory pressure of the patient but it ranges from 12 to 40%. The
efficiency of delivery is higher for active (battery-driven) DPIs
since the powder dispersion does not depend on the inspiratory
pressure of the patient.
For animal studies, the Dry Powder Insufflator™, a unique
device patented by (Philadelphia, PA) is used to deliver ther-
apeutic powders by direct administration (Cryan et al., 2007).
The main body of the insufflator has a small chamber that is
filled manually with a small amount of pre-weighed dry powder.
The powder is then dispersed in the chamber of the insufflator
by applying small “puffs” of air with an empty plastic syringe.
The insufflator can be used to deliver powders of different sizes,
from nano-particles (Tetsuya and Hiroaki, 2006) to large porous
particles (Codrons et al., 2004). The particle size distribution
of the insufflated powders are essentially unaffected by passage
through the device, as measured by a variety of sizing techniques
(Codrons et al., 2004; Tetsuya and Hiroaki, 2006; Lu et al., 2007).
Our group has employed this device to study the disposition of
a number of anti-tubercular compounds when delivered by the
pulmonary route to guinea pigs, including rifampicin (García-
Contreras et al., 2006a; Sung et al., 2009b), capreomycin (Garcia-
Contreras et al., 2007, 2012; Fiegel et al., 2008), and PA-824
(Sung et al., 2009a). For multiple administration of aerosolized
powders by passive inhalation to multiple rodents, Hickey et al.
designed the dry powder dispersion chamber (Garcia-Contreras
et al., 2007). The design is similar to that of the nose-only expo-
sure chamber but the volume of the reservoir is smaller and the
powder is dispersed without the need of external air to achieve
a highly concentrated standing cloud of the therapeutic pow-
der. This novel chamber has been used to deliver daily doses of
capreomycin (Garcia-Contreras et al., 2007) and PA-824 (Garcia-
Contreras et al., 2010) for four weeks to treat TB-infected guinea
pigs. The results of these studies will de discussed in subsequent
sections.
FORMULATION OF ANTI-TUBERCULAR DRUGS AND
VACCINES FOR INHALATION
The preparation of novel inhaled therapeutics into dry powders is
the most viable approach to produce stable dosage forms because
there are a number of ways to manufacture them and scale up
their production if needed. As mentioned before, powder formu-
lations have greater stability than liquid formulation and usually
do not require refrigeration. They are typically packed in such a
way that protects them from light and humidity, which enhances
their stability. Dry powders for inhalation can be prepared by
micronization of the drug, or formulation into particles of dif-
ferent sizes and compositions, which also allows the control of
their release from such systems. Micronized antibiotics have to
be prepared into a blend with a carrier, usually lactose, in order
to be dispersed, and efficiently inhaled. Micronized gentamicin
powders have been delivered by the pulmonary route for the treat-
ment of infections associated with cystic fibrosis (Goldman et al.,
1990), but there are no reports of the use of micronized antibiotics
for TB treatment. There are a considerable number of reports
in the literature formulating anti-tubercular drugs and vaccines
into microparticles and nanoparticles of different compositions
for pulmonary delivery. For drugs, these formulations most com-
monly employ first line agents such as rifampicin, isoniazid, and
pyrazinamide, but other second and third line drugs have also
been investigated (Table 1). Particle cores are made of biodegrad-
able polymers, lipids, sugars or aminoacids, and microparticles
are more employed than nanoparticles.
Most of these particles were manufactured essentially by emul-
sification/solvent evaporation or spray drying, or a variation of
these. The emulsification/solvent evaporation is a simple method
that involves emulsification of a dispersed phase in which the core
of the particle and the drug have been dissolved or dispersed into
a continuous phase in which neither the drug or core material are
soluble (Watts et al., 1990). The two phases are then emulsified at
a high speed with a specialized mixer and the mixing is contin-
ued until the solvent in the dispersed phase is evaporated and the
particles are hardened or formed. Particles are then collected by
filtration, centrifugation, or other method specific for the particle
size. For particles with core made of the poly lactic acid or any of
its co-polymers with the poly glycolic acid (PLGA), the polymer
is typically dissolved in methylene chloride (dispersed phase) and
an aqueous solution, with or without a surfactant, is used as the
continuous phase (Bodmeier andMcGinity, 1987). Depending on
the proportion of phases, the target particle size, and the method
of particle collection different emulsifiers can be used, includ-
ing polyvinyl alcohol (PVA), methyl cellulose, polysorbate 80,
sodium oleate, and sodium dodecyl sulfate. The type of mixing
process, the mixing speed, the concentration of the emulsifier,
and the concentration of the core material in the dispersed phase,
will together determine the final size and distribution of the
resulting particles (Jalil and Nixon, 1990). Rifampicin micropar-
ticles for pulmonary delivery were prepared by this method using
rifampicin and PLGA dissolved in methylene chloride as the dis-
persed phase to form the core of the particle and the continuous
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Table 1 | Novel inhalable formulations for anti-tubercular drugs.
Drug Formulation Results References
Rifampicin Poly(lactide-co-glycolide)
microspheres
Single and double doses resulted in significantly
reduced numbers of viable bacteria and lung
damage
O’Hara and Hickey, 2000;
Suarez et al., 2001a,b
– Poly(lactide-co-glycolide)
microspheres
Drug release accelerated by adsorption of
pulmonary surfactant onto particles
Tomoda and Makino, 2007
– Poly(lactic acid)
microparticles
Optimization of parameters of manufacture Patomchaiviwat et al., 2008
– poly(lactic-co-glycolic acid)
nanoparticle-containing
mannitol microspheres
One-step preparation of microspheres; effective
uptake by rat alveolar macrophages
Ohashi et al., 2009
Isoniazid and Rifampicin Poly(D,L-Lactic
Acid) microparticles
Particles taken up by cultured macrophages and
intracellular drug concentrations higher than with
drug alone
Sharma et al., 2001
Rifampicin, isoniazid, and
pyrazinamide
Poly(DL-lactide-co-glycolide)
nanoparticles
A single dose resulted in therapeutic plasma levels
for 6–8 days and in the lungs for up to 11 days
Pandey et al., 2003
– Solid lipid nanoparticles
made of stearic acid
A single dose resulted in therapeutic plasma levels
for 5 days and in lungs, liver, and spleen for 7 days
Pandey and Khuller, 2005
– Nanoparticles made of
sodium alginate
A single dose resulted in lung, liver, and spleen
concentrations above MIC for 15 days
Zahoor et al., 2005
Isoniazid and rifabutin Poly(lactic acid)
microparticles
High drug payload released over 10 days; drug
concentration in macrophages 20-fold larger than
with solutions
Muttil et al., 2007
Para-aminosalicylic
acid (PAS)
Large porous particles made
of DPPC
PAS remains at
therapeutic concentrations in the lung tissue for at
least 3 h after insufflation
Tsapis et al., 2003
Capreomycin sulfate Poly(lactide-co-glycolide)
microspheres
Large porous microspheres in respirable sizes
prepared by a simple method
Giovagnoli et al., 2007
– Porous particles made of
leucine and DPPC
Good aerosolization and stability properties.
Longer half-life in guinea pigs
Fiegel et al., 2008
– – Significantly smaller lung bacterial burden,
inflammation, and histopathological damage than
IM controls
Garcia-Contreras et al., 2007
PA-824 Porous particles made of
leucine and DPPC
Easily dispersable particles. Half life 2-fold longer
after pulmonary administration than by oral
gavage. Drug present in lung even after plasma
levels were undetectable.
Sung et al., 2009a
– – Animals treated with inhaled particles had smaller
degree of inflammation and histopathology
damage than those receiving oral treatment.
Garcia-Contreras et al., 2010
phase consisted of an aqueous glycerol solution containing PVA
as the emulsifier (O’Hara and Hickey, 2000). The two phases
were mixed at 5000 rpm for 45min and the particles collected
by filtration. The resulting particles had a volume diameter of
3.45–6.84μm and were considered appropriate for pulmonary
delivery.
Themain limitations of the emulsification/solvent evaporation
method are the size of the batches that can be manufactured at
once and the number of materials that can be employed as core
for the particles. In the past decades a number of alternative tech-
niques for themanufacture of particles have emerged and the field
has been named “Particle Engineering.” A few of the advantages
of engineered particles are scalability of the methods, enhanced
physical and chemical stability of particles, better control of the
time of drug release, and in many cases improved bioavailabil-
ity (Van Oort and Sacchetti, 2007). Spray drying in particular has
been a popular technique to manufacture respirable particles due
to the variety of materials that can be employed and the range
of particle sizes and batch sizes that can be produced. Spray dry-
ing is a one-step process that produces particles from a liquid feed
(VanOort and Sacchetti, 2007). Typically, the liquid feed is a solu-
tion or suspension that is atomized to form a spray that is placed
Frontiers in Cellular and Infection Microbiology www.frontiersin.org September 2012 | Volume 2 | Article 118 | 6
Hanif and Garcia-Contreras Therapeutic aerosols for Tuberculosis
in a contained hot gaseous environment. The spray droplets are
dried to form solid particles that are classified by size by means
of a cyclone, bag filter, or electrostatic precipitator. The drying
temperature, atomization pressure, gas flow, and composition of
the liquid feed can be manipulated to produce particles with dif-
ferent characteristics (Garcia-Contreras et al., 2006b). A number
of particles containing anti-tubercular agents have been manu-
factured by spray drying (Table 1), including rifampicin (O’Hara
and Hickey, 2000; Suarez et al., 2001a,b), capreomycin (Fiegel
et al., 2008), PA-824 (Sung et al., 2009a), para-aminosalicylic acid
(Tsapis et al., 2003), and combinations of rifampicin-isoniazid
(Sharma et al., 2001), and rifampicin-isoniazide-pyrazinamide
(Pandey et al., 2003). Other particle engineering techniques such
as spray freeze drying have been developed for heat sensitive
molecules (proteins and peptide drugs or vaccines) from vari-
ations of the settings and parameters of spray drying (Garmise
et al., 2007).
In addition to the enhanced stability, one of the most attractive
advantages to formulate vaccines as dry powders for inhalation
is that the antigen presenting cells in the lung (macrophages
and dendritic cells) tend to uptake particulate forms that are
inhaled as part as their house-keeping function. This event can
make particles act as adjuvants because depending on their com-
position and residence time it enhances the immune response
greatly in comparison to soluble antigens. Microparticulate
systems are known to stimulate the immune response to help
Th1 induction (Raychaudhuri and Rock, 1998). Antigens alone
or with other adjuvants have been associated or encapsulated
in micro- or nano-particles made of lipids, polymers, sugars,
aminoacids, or viral vectors. In addition to providing adjuvancy,
the encapsulation of antigens into particles has other advan-
tages for pulmonary delivery such as protecting the integrity
of antigens, improving the aerosol dispersion of the particles
and lung deposition, and in cases even control the time and
amount of antigen released from these particles. Despite all these
advantages, only a handful of novel vaccines against TB have
been formulated into particles for pulmonary administration
(Table 2).
ADVANCES IN THE PREVENTION AND TREATMENT OF
AND VACCINES
CAPREOMYCIN POWDER AEROSOLS
Initial studies investigated the disposition of capreomycin in
healthy guinea pigs to define initial PK parameters, which will
require subsequent evaluation and redefinition in infected ani-
mals. PK studies indicated that, 2 h after receiving the dose,
capreomycin plasma concentrations in guinea pigs were simi-
lar after i.v. and pulmonary administration (Garcia-Contreras
et al., 2007). Capreomycin was also cleared at a lower rate
Table 2 | Novel anti-TB vaccine formulations for pulmonary administration.
Vaccine Formulation Results References
SUBUNIT VACCINES
HLA-A*0201-restricted T-cell
epitopes derived from MTB
antigens: 19 kD, Ag85B
(2 epitopes), Ag85A, PstA1,
ThyA and RpoB, and ESAT-6
Chitosan-DNA nanoparticles Levels of IFN-gamma after spray instillation of a
suspension of these nanoparticles were much
higher in transgenic mice compared to those after
spray instillation of the nanoparticles alone or the
plasmid by IM injection
Bivas-Benita et al., 2004
Ag85 + trehalose
dibehenate
PLGA microspheres PLGArAg85B microspheres induced the specific
hybridoma cells to produce IL-2 at a level that was
two orders of magnitude larger than the response
elicited by soluble rAg85B
Lu et al., 2007
– – A strategy of BCG prime-PLGArAg85B aerosol
boost appeared to enhance protection from
bacterial infection, as indicated by a reduction in
CFU in both the lungs and spleens compared with
untreated controls
Lu et al., 2010
DNA encoding the MTB
latency antigen Rv1733c
PLGA-polyethyleneimine
nanoparticles
Rv1733c DNA-PLGA–PEI nanoparticles increased
T cell proliferation and IFN-γ production more
potently compared to the same vaccinations
given IM
Bivas-Benita et al., 2009
WHOLE INACTIVATED BACTERIA
BCG Danish strain Leucine microparticles The bacterial burden of lungs of animals
immunized by the pulmonary route with BCG
particles was significantly lower than that of
animals immunized by BCG SC or untreated
controls. Histopathological analysis showed very
few and small areas affected by granulomas in
animals vaccinated by pulmonary route, compared
to those vaccinated SC
Garcia-Contreras et al., 2008
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when delivered by the pulmonary route than when given i.v. or
i.m., resulting in a significantly longer t1/2. Thus, it was pro-
posed that given the comparably high drug concentrations in
the lungs achieved by inhalation relative to those reported for
other inhaled TB drugs (Tsapis et al., 2003) and the relatively
good bioavailability achieved by inhalation, efficacy might be
achieved in an infection model at an inhaled dose below the dose
required to achieve efficacy by conventional parenteral routes
of delivery. To test this hypothesis, capreomycin was delivered
by aerosol and injection to TB- infected guinea pigs daily for
four weeks (Garcia-Contreras et al., 2007). The lungs of ani-
mals receiving the highest aerosol dose of capreomycin showed
significantly smaller degrees of inflammation, bacterial burdens
(CFU/ml), and percentages of lung tissue affected by granulo-
mas and caseous necrosis (by histopathology) than those for
any other treatment. In contrast, only animals treated by i.m.,
injection showed a significantly reduced bacterial burden in the
spleen. However, histopathological analysis of spleens revealed
a positive effect of treatment with the high dose of capre-
omycin particles and the i.m., solution. The modest effect in
the spleen was attributed to the low systemic concentrations
of the drug in animals receiving dry powder aerosols and the
actual deposited dose of the drug in the alveoli. It was estimated
that the actual deposited doses of aerosolized capreomycin were
10-fold smaller because the aerosols to treat TB-infected animals
were delivered by passive inhalation, whereas the PK studies were
performed delivering capreomycin aerosols by a direct adminis-
tration bolus (Garcia-Contreras et al., 2007). Therefore, there is
reason to believe that deposition of sufficient drug in the lungs
of guinea pigs would potentially result in therapeutic systemic
concentrations.
DRY POWDER PA-824 AEROSOLS
PA-824, typically administered orally, demonstrates great promise
in treating both active and latent TB, with the potential of
also treating MDR-TB. We postulated that by delivering drug
containing powders directly to the lungs, high concentrations
could be achieved to treat the bacteria locally, thus minimizing
systemic exposure (Garcia-Contreras et al., 2010). PA-824 was
formulated into a stable dry powder porous particle form for
delivery by the pulmonary route via simple DPIs. This formu-
lation showed to maintain physical, aerodynamic, and chemical
stability at room temperature for six months and under refrig-
erated conditions for more than one year (Sung et al., 2009a).
TB infected guinea pigs were treated with the different PA-824
formulations by the oral and pulmonary routes daily for four
weeks. The treatment was well tolerated and no adverse effects
were observed in any of the animals. Treatment with aerosolized
PA-824 particles appeared to reduce manifestations of disease
in the lungs and spleens of guinea pigs. Animals receiving low
and high doses of inhaled PA-824 aerosols showed significantly
less inflammation (as indicated by wet tissue weights), a lower
number of viable bacteria, and less tissue damage (as shown by
histopathological analysis) than untreated animals or those inhal-
ing placebo particles. Furthermore, bacterial burden was even
lower in the spleens of animals that inhaled the high dose of
PA-824 particles than in those that inhaled the low dose, and
tissue damage was observed to a lesser extent in those animals
as well.
AEROSOLIZED VACCINES AGAINST TB
The BCG powder vaccine, manufactured by Wong et al. (2007)
was administered to guinea pigs by the pulmonary route (Garcia-
Contreras et al., 2008) and its protective effect compared to that
after the traditional intradermal immunization. Animals were
challenged with MTB H37Rv aerosols six weeks after immu-
nization and necropsy performed four weeks after challenge.
Bacteriological analysis showed that the bacterial burden in the
lungs of all immunized animals was significantly lower than that
of unimmunized controls, regardless of the BCG dose or the
route of immunization. Most importantly, the bacterial burden
of lungs of animals immunized by the pulmonary route with
BCG particles was significantly lower than that of animals immu-
nized by the traditional intradermal route. Histopathological
analysis supported the bacteriology results, showing few gran-
ulomas in the lungs of animals vaccinated by the intradermal
route, whereas the lung tissue appeared almost normal in animals
immunized by the pulmonary route.
The role of alveolar macrophages as initial host cells for MTB
was studied in a vaccine strategy with a subunit antigen. PLGA
micro-particles were manufactured in respirable sizes as carriers
for recombinant Ag85B (rAg85B) to be delivered by pulmonary
route as a novel vaccine against TB (Lu et al., 2007). Continuous
release of antigens from PLGA has shown to provide a pro-
longed immunological response in animals avoiding the need for
multiple boosting (Shahin et al., 1995; Men et al., 1996). The
ability of these r-Ag85B-PLGA microspheres to deliver antigen to
macrophages for subsequent processing and presentation to the
specific CD4 was assessed in the T-hybridoma cells DB-1. These
cells recognize the Ag85B97-112 epitope presented in the context
of MHC class II and secrete IL-2 as the cytokine marker. THP-1
macrophage-like cells exposed with r-Ag85B-PLGA microspheres
induced production of IL-2 at a level that was two orders of mag-
nitude larger than the response elicited by soluble rAg85B in DB-1
cells (Lu et al., 2007). These results suggested that dry powder
delivery of rAg85B using a microsphere formulation had poten-
tial as a vaccine strategy for preventing TB or to be employed as a
promising boosting vaccine.
The potential of aerosolized r-Ag85B-PLGA microspheres
to protect against TB was evaluated in the guinea pig model
employing prime-boost strategies with BCG and r-Ag85B-PLGA
microparticles (Lu et al., 2010). The r-Ag85B-PLGA micro-
particles were prepared in sizes suitable for inhalation and deliv-
ered as aerosolized dry powders to the lungs of guinea pigs in
single or multiple doses in homologous and heterologous immu-
nization strategies. Immunized animals were challenged with a
low-dose aerosol ofMTBH37Rv to assess the extent of protection.
The heterologous strategy of BCG prime-r-Ag85B-PLGA aerosol
boosts appeared to enhance protection from bacterial infection,
as indicated by a reduction in the bacterial burden in both the
lungs and spleens of immunized animals compared with non-
vaccinated animals. Even though the bacterial burdens were not
statistically different between the BCG and BCG-BCG groups,
histopathological and morphometric analyses of lung and spleen
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tissue indicated the positive effect of BCG-P-rAg85B immuniza-
tion by measuring a smaller area of tissue affected and number
and size of granulomas observed in the tissues of animals immu-
nized by the pulmonary route. Therefore, it was suggested that
direct pulmonary immunization using these particles enhanced
the protection afforded by primary immunization with BCG
against TB infection in this animal model. Since a large pro-
portion of the population of the world has been immunized
with BCG as infants, an aerosol boost may be a promising strat-
egy to enhance and prolong the protective immunity based on
BCG-initiated immunity (Lu et al., 2010).
CONCLUSIONS
The advantages of aerosol administration of drugs and vac-
cines for TB treatments are supported by the different aspects
presented in this review. These include: (1) higher drug con-
centrations at the main site of infection limiting systemic side
effects, and (2) enhanced protection with the convential vaccines
and possible vaccine strategy using subunit vaccines for immune-
compromised patients. These advantages are not only clinical, but
also pharmaceutical offeringmore stable formulations and dosage
forms that can be stored without refrigeration for their use in
regions of the world where the burden of TB infection is high.
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